Anti-MDA5 Antibody-Positive Dermatomyositis in Emirati Patients: A Case Series Highlighting Clinical Variability

Abstract

Case series

Patients: Male, 24-year-old • Male, 62-year-old • Male, 13-year-old

Final Diagnosis: Dermatomyositis • interstitial lung disease

Symptoms: Rash • respiratory deterioration • weakness

Clinical Procedure: —

Specialty: Rheumatology

Objective: Unusual clinical course

Background

Melanoma differentiation-associated gene 5 (MDA5) is an intracellular sensor that detects double-stranded RNA viruses and triggers type I interferon pathways. Anti-MDA5 dermatomyositis (MDA5-DM) is an uncommon autoimmune subtype, often linked to rapidly progressive interstitial lung disease (RP-ILD) and sometimes presenting without obvious muscle weakness. It can appear in pulmonary, cutaneous–articular, or vascular forms, with RP-ILD carrying the worst prognosis. We describe 3 Emirati patients with MDA5-DM, each with a different clinical picture, organ involvement, and outcome.

Case Reports

Case 1: A 24-year-old man developed flu-like symptoms, rash, abnormal liver enzymes, and RP-ILD. His condition worsened despite high-dose steroids, cyclophosphamide, and plasma exchange; he required ECMO and died after 40 days. Case 2: A 62-year-old man with ILD presented with worsening dyspnea, weakness, and rash. He had high ferritin and lactate dehydrogenase levels, with positive anti-MDA5. He was treated with steroids, rituximab, nintedanib, and mycophenolate. High-resolution computerized tomography scans remained stable, but he required long-term oxygen after having pneumonia. Case 3: A 13-year-old boy had weight loss, stiffness, rash, and positive anti-MDA5. Magnetic resonance imaging confirmed myositis. He improved after steroids and intravenous immunoglobulin, with recovery of strength, weight gain, and normal function after prolonged treatment.

Conclusions

MDA5-DM is a rare and clinically diverse entity that can range from indolent skin-limited disease to life-threatening RP-ILD. This case series highlights the full clinical spectrum, from pediatric onset to fulminant adult disease. Multidisciplinary care, awareness of atypical presentations, and continued research into disease mechanisms and therapeutics are essential to improving survival in MDA5-DM.

Introduction

Melanoma differentiation-associated gene 5 dermatomyositis (MDA5-DM) is a distinct subset of dermatomyositis characterized by 3 recognized clinical phenotypes – predominantly pulmonary, skin–articular, or vascular. Unlike patients with classic dermatomyositis, many patients with MDA5-DM have minimal or no muscle weakness, and muscle enzyme levels can remain normal. Among its manifestations, rapidly progressive interstitial lung disease (RP-ILD) is the most severe complication, occurring far more frequently in MDA5-DM than in MDA5-negative cases and strongly influencing survival [1]. The disease appears to develop in genetically predisposed individuals following an environmental trigger. Viral double-stranded RNA is a known activator of MDA5 pathways, leading to type I interferon overproduction and, in some cases, the generation of anti-MDA5 autoantibodies [2]. In recent years, interest has grown in the possible role of SARS-CoV-2 infection or vaccination in triggering this immune cascade, although causality remains unproven [3]. In our series, 2 patients had recent viral exposure, and 1 patient had received a COVID-19 vaccine prior to onset. Clinical presentation can be subtle or aggressive, ranging from skin-limited disease to fulminant RP-ILD. Prognostic factors such as anti-Ro52 positivity, hyperferritinemia, and elevated lactate dehydrogenase (LDH) levels have been associated with poorer outcomes [4]. Early and aggressive immunosuppression – often with high-dose corticosteroids, calcineurin inhibitors, and cyclophosphamide – has been shown to improve short-term survival, while emerging options such as Janus kinase (JAK) inhibitors and tocilizumab may offer benefits in refractory cases [5–8]. We present 3 Emirati patients with MDA5-DM, each representing a different point on the disease spectrum, with 1 fatal case of RP-ILD, 1 chronic case of RP-ILD, and 1 pediatric-onset case with good recovery after prolonged treatment. This series of 3 cases of MDA5-DM in an Emirati population and underscores the heterogeneity of presentation and outcome and highlights the importance of early recognition and tailored therapy in improving survival.

Case Reports

Case 1

A 24-year-old Emirati man with a medical history of controlled asthma had a history of recent flu-like symptoms. He was seen in another facility, was found to have elevated liver enzymes, and was treated at that time for a possible viral infection. Flu symptoms subsided, and he then presented to our facility 1 month later with a 2-week history of a progressive lower limb rash that was preceded by 1 week of fever, fatigue, nausea, and dark urine. He had also had bilateral wrist swelling with no pain or redness that resolved completely. The patient also noted waking up in the morning with puffy eyes. Physical examination revealed vaguely defined erythematous patches in the eyebrows, a petechial rash on both hands, and diffuse dusky erythematous maculopapular exanthema over the lower limbs (Figure 1), sparing the genitalia and plantar surface of the feet. He was afebrile, and vital signs were within normal limits. His chest examination was normal, and on neurological examination, no weakness or abnormalities were noted. At that time, laboratory test results revealed hypoalbuminemia (albumin, 24 g/dL), mildly raised liver enzymes, elevated LDH level of 443 IU/L, elevated ferritin level of 1153 mcg/L, elevated C-reactive protein (CRP) level of 10 mg/L, elevated thyroid-stimulating hormone level of 6 IU/L, and an elevated erythrocyte sedimentation rate (ESR) of 35 mm/h. Complete blood count results exhibited thrombocytopenia (platelet count, 91×10⁹) and lymphopenia (white blood cell count, 0.48×10⁹), and blood smear revealed no evidence of schistocytes. As the patient reported having slight lower leg heaviness, a creatine kinase level was requested and was found to be within the reference range. Furthermore, all microbiology investigations, including SARS-CoV-2 and HIV polymerase chain reaction test results, were negative. On admission, a chest X-ray was requested and showed no abnormalities.

Figure 1.

Findings on physical examination of petechial rash on both hands and diffuse dusky erythematous maculopapular exanthema over the lower limbs.

On day 2 of admission, the patient underwent arterial blood gas testing due to shortness of breath and worsening cough, which revealed type 1 respiratory failure with hypoxia (PaO₂, 66 mmHg). High-resolution computerized tomography (HRCT) revealed patchy ground-glass opacities in the bilateral lower lobe mixed with airspace opacities. A multidisciplinary team agreed to begin the patient on empiric antibiotics for an atypical pneumonia. The pulmonology team suggested bronchoalveolar lavage, and the nephrology team arranged for a kidney biopsy. On day 3, the patient was moved to a high-dependency unit and placed on a high-flow nasal cannula delivering 70% oxygen. An autoimmune workup revealed a positive indirect immunofluorescence antinuclear antibody (ANA) speckled pattern and positive anti-Ro and anti-MDA5 antibodies. The patient was started on intravenous (IV) methylprednisolone 1 g every 24 hours, after a diagnosis of MDA5-DM with RP-ILD and renal impairment. Plasma exchange was started, and afterward he was started on cyclophosphamide 1 g and tacrolimus 4 mg twice daily on day 5. He initially improved on this regimen, but his condition suddenly declined after 10 days, leading to a comprehensive septic workup. Intravenous antibiotics were initiated, and a CT scan revealed progression of ground-glass opacifications (Figure 2). Vancomycin and Pneumocystis jirovecii pneumonia treatments were initiated, and administration of a second dose of cyclophosphamide was considered. However, given the uncertainty regarding whether the patient’s clinical deterioration was due to a hospital-acquired infection or progression of the underlying autoimmune process, intravenous immunoglobulin (IVIG) was initiated at a dose of 0.4 g/kg, with a planned course of 5 days. Unfortunately, he was transferred to the intensive care unit (ICU) and put on mechanical ventilation on day 20 of admission. His condition continued to worsen, and he was transferred to another facility for extracorporeal membrane oxygenation. We were unable to view the progress of the patient in the other facility due to the limited access; however, the imaging studies performed throughout his stay were readily accessible and showed further deterioration in his clinical condition, including complete consolidation and whiteout of both lungs, indicative of worsening acute respiratory distress syndrome, the superimposed development of multiple cavitary lesions suggestive of necrotizing pneumonia, pneumomediastinum, bilateral pneumothorax, and multiple pseudoaneurysms in the subclavian artery. The patient was in the hospital for approximately 40 days before his death.

Figure 2.

Follow-up high resolution computerized tomography of the chest in patient 1 showing interval worsening of ground-glass opacities and development of consolidations despite aggressive immunosuppressive therapy.

Case 2

A 62-year-old Emirati man presented with 8 months of widespread lethargy, poor appetite, night sweats, subjective fever, exertional dyspnea, and a wet cough with yellow phlegm. The patient had lost 10 kg. He also reported hand joint pain and swelling, but no morning stiffness or erythema. He denied sick contact or recent travel history. He was a previous smoker with a 14-year history of smoking and did not take alcohol. He appeared cachectic, with facial muscular atrophy, and weighed 55 kg. His heart rate and blood pressure were normal, along with a respiratory rate of 24 breaths per minute on a 1-L nasal cannula. Hand examination revealed left ulnar deviation, right third proximal interphalangeal swelling, and bilateral metacarpophalangeal pain (Figure 3). Hyperpigmented macular rash appeared on the eye, neck, and back. During the neurological examination, he exhibited proximal upper and lower limb weakness, preserved reflexes, and intact sensation and was able to rise from a seated position. Laboratory test results showed normal kidney function, hypoalbuminemia (albumin, 17 g/L), increased LDH (630 IU/L) and ferritin (1366 mcg/L) levels, normal aldolase and creatine kinase levels, an ESR of 59 mm/h, and a normal CRP level. The immunology investigations reported positive anti-CCP antibody (>200), positive ANA titers of 1: 160 with speckled and cytoplasmic patterns, positive anti-MDA 5 and anti-Ro52, and negative rheumatoid factor. All infectious workup was negative except for hepatitis B core antibody. A CT scan of the chest, abdomen, and pelvis revealed diffuse mediastinal lymph node enlargement, prominence of axillary lymph nodes bilaterally, moderate-sized pericardial effusion, and a right-sided thyroid lesion HRCT demonstrated bilateral ground-glass opacities predominantly in the lower lobes, consistent with interstitial lung disease in anti–MDA 5 dermatomyositis (Figure 4). A bilateral hand ultrasound revealed synovial thickening and irregularities in the proximal interphalangeal joint of the right middle finger, suggesting arthritis. Magnetic resonance imaging (MRI) of the thighs revealed reduced muscle bulk, abnormal signal alteration, and post-contrast enhancement of the intramuscular septum, suggesting myositis-like muscular inflammation. Echocardiography showed severe pulmonary hypertension with pulmonary artery pressure of 60 mmHg and mild pericardial effusion. The patient underwent further investigations to rule out malignancy, including colonoscopy, esophagogastroduodenoscopy, and CT of the neck. CT showed a large retrosternal and mediastinal thyroid, and thyroid nodule biopsy showed a benign lesion. Tumor markers were negative.

Figure 3.

Clinical photograph of patient 2’s hands showing dry, hyperpigmented patches over the metacarpophalangeal joints and Gottron papules.

Figure 4.

High resolution computerized tomography of the chest in patient 2 demonstrates bilateral ground-glass opacities predominantly in the lower lobes, with features consistent with interstitial lung disease in anti–melanoma differentiation–associated protein 5 antibody dermatomyositis.

Given the clinical picture and positive anti-MDA5 antibodies with anti-Ro52, the treatment strategy for MDA5-DM was established based on the clinical picture. The patient was given 500 mg of methylprednisolone for 3 days, followed by a tapering dosage of prednisolone. One cycle of rituximab was administered as induction therapy, and entecavir was administered prior to induction. Therapeutic approaches improved the patient’s fatigue and mobility. The patient could walk without assistance, despite proximal muscle weakness. He was discharged on room air after being on 3 L of oxygen for several days. Outpatient pulmonology assessment revealed a restrictive pattern in the pulmonary function test (52%; lung volumes and diffusion capacity could not be obtained). HRCT was indicative of RP-ILD (Figure 5). The patient was put on nintedanib 150 mg twice daily and advised to start on mycophenolic mofetil. After 2 months of treatment, he developed pneumonia and required hospitalization. His clinical condition worsened in the form of weakness, shortness of breath, and hypoxia, necessitating initiation of rituximab and prednisolone.

Figure 5.

High resolution computerized tomography with bilateral ground-glass opacities predominantly in the lower lobes, suggestive of interstitial lung disease.

Case 3

A 13-year-old Emirati boy with glucose-6-phosphate dehydrogenase deficiency and thalassemia presented to the emergency department with a 3-month history of colicky abdominal pain, hand joint stiffness, pain in the knees, ankles, elbows, and shoulders, difficulty walking, praying, and doing daily chores. He had lost 7 kg in a month due to a decline in appetite and had excessive thirst and urination. The patient was also socially isolated, not attempting to communicate with family members, and was slow, according to the mother. He had recently been exposed to a COVID-positive individual, but additional SARS-CoV-2 polymerase chain reaction test results and serology testing came back negative. Recent blood test results at another facility revealed elevated liver function tests, leukopenia, neutropenia, and lymphopenia. On examination, the patient appeared cachectic, underweight, and frail, weighing 35 kg, less than the 10^th percentile on the growth chart. In contrast to typical dermatomyositis skin lesions, he had hyperpigmentation on his neck, buttocks, elbows, knees, and knuckles. The patient’s gait was normal, but he appeared weak and frail with poor posture. Hand examination revealed proximal interphalangeal and distal interphalangeal pain and stiffness bilaterally, with the left hand significantly worse than the right; no joint swelling was noted. Lower limb examination revealed proximal muscle weakness power of 4+ bilaterally, with slow reflexes; no joint swelling or tenderness was observed. His abdomen was soft and lax with no organomegaly, but he had mobile, enlarged bilateral inguinal lymph nodes. The patient’s chest was clear on examination, with a normal heart rate and rhythm.

Laboratory test results showed elevated levels of lipase (110 IU/L), alkaline phosphatase (182 IU/L), aspartate aminotransferase (484 IU/L), alanine aminotransferase (343 IU/L), LDH (465 IU/L), and ferritin (1230 mcg/L). The creatine kinase level was in the normal range. Requested inflammatory markers showed a mildly raised ESR of 14 mm/h, with normal CRP and procalcitonin levels. The complete blood count showed hypochromic microcytic anemia, leukopenia (white blood cells, 2.97×10⁹/L), mild neutropenia (neutrophils, 1.15×10⁹/L), and lymphopenia (lymphocytes, 1.27×10⁹/L), with a positive direct antiglobulin test. Chest X-ray and abdominal ultrasound findings were normal. Further investigations requested by multiple teams resulted in negative COVID-19 serology, positive Epstein-Barr virus (EBV) capsid antigen immunoglobulin G (IgG), and negative EBV capsid antigen immunoglobulin M (IgM). Extractable nuclear antigen panel, ANA, double-stranded DNA antibody, antineutrophil cytoplasmic antibody, cardiolipin IgG and IgM, beta-2 glycoprotein IgG and IgM, anti-CCP antibody, rheumatoid factor, thyroglobulin antibody, thyroid peroxidase antibody, human leukocyte antigen B27, and immunoglobulin subclasses were all within normal limits. He had normal kidney function, with a negative urine protein to creatinine ratio. The myositis panel was still pending. Imaging included an echocardiography, which showed no abnormal findings, and ultrasound of the joints, which showed mild subcutaneous soft tissue edema with skin thickening. The bone marrow biopsy revealed no myeloid cells. Intravenous hydration moderately improved the patient’s condition, and he was discharged on day 10 with outpatient follow-up. MRI of the thighs and a myositis panel were still pending.

Upon follow-up, the patient’s joint pain, appetite, and overall health had improved, and the myositis panel resulted positive for the anti-MDA5 antibody. The rheumatologist recommended an urgent thigh MRI and follow-up appointment in a week, but the patient was lost to follow-up for 8 months. During this time, he was started on oral prednisolone 20 mg daily and oral methotrexate 10 mg. He presented once more with new rashes, including the knuckle Gottron papules and heliotrope sign. He still exhibited proximal muscle weakness and joint stiffness and pain. We intended to start the patient on IVIG at a dose of 2 g/kg, but due to a global shortage during the COVID pandemic, we were able to give him 1.5 g/kg instead, which was continued every 4 weeks. He was also started on IV methylprednisolone 30 mg/kg over 3 days, followed by oral steroids. He was referred for a respiratory evaluation to rule out ILD. HRCT showed no evidence of consolidation, mass, ground-glass opacification, pleural effusion, or pneumothorax. There was no evidence of ILD; however, tiny subcentimeter nodules were noted along the bilateral fissures and the basal portion of the left lower lobe. Moreover, a lung function test did not fulfill the American Thoracic Society criteria, with a forced expiratory volume in 1 second to forced vital capacity ratio of 85%.

After 4 IVIG doses, he stopped taking methotrexate and prednisolone, and then stopped attending IVIG sessions for 2 months. He improved at sitting and walking and had slight back and knee pain despite his fragility, fatigability, and muscle atrophy. IVIG was restarted, and appointment adherence was discussed. His clinical condition improved after 10 months of therapy. In addition to his physical activities, his social communication improved tremendously. His appetite improved, and he gained nearly 15 kg, putting him in the 29^th percentile on the growth chart. MRI of the thighs was repeated after 8 sessions of IVIG and showed significant improvement (Figure 6), with the muscle edema completely gone and no abnormal contrast enhancement. The treatment plan was adjusted, and steroids were tapered, in addition to the patient remaining on oral methotrexate and monthly IVIG infusions.

Figure 6.

Follow-up magnetic resonance imaging of the thigh muscles in patient 3 after treatment, showing complete resolution of previous signal changes, correlating with clinical improvement.

Discussion

This case series highlights the clinical heterogeneity of MDA5-DM and the spectrum of disease phenotypes ranging from RP-ILD to cutaneous-limited forms and systemic inflammatory features. Our 3 patients, all of Emirati descent, presented distinct clinical paths – mirroring known phenotypes and outcomes described in recent literature [1,4,9]. Recent studies emphasize the pathogenic role of MDA5 activation via viral RNA sensing pathways, particularly type I interferon overproduction, as a central mechanism [1]. This has prompted new interest in early interferon blockade and multi-target immunosuppression. Ro52 positivity, present in 2 of our patients, remains a poor prognostic factor for ILD severity [4]. Biomarkers such as elevated ferritin, LDH, and interleukin 18 have been reinforced as indicators of disease activity and mortality [4]. Our first patient’s hyperferritinemia and early Ro52 positivity likely contributed to a poor outcome, despite aggressive therapy. Interestingly, while the role of COVID-19 or its vaccine in triggering MDA5 autoimmunity remains speculative, recent immunological reports suggest that mRNA vaccines and SARS-CoV-2 infections can activate MDA5 pathways [3]. However, direct causality is not yet confirmed. This series reflects real-world complexities in which overlapping autoimmune, infectious, and nutritional factors complicate early recognition. Long-term IVIG and methotrexate administration helped stabilize our pediatric patient, although delayed follow-up affected outcomes.

All the patients in our case series had positive anti-MDA5 antibodies based on myositis profiles completed by the same facility. In recent decades, many myositis-specific antibodies have been identified, and their greater significance has been elucidated. Each myositis-specific antibody is associated with distinct clinical features that help us not only to diagnose idiopathic inflammatory myositis but also to sub-classify patients with myositis into several clusters with a uniform clinical or pathophysiological background [1,10]. MDA5 is a key immune protein that triggers interferon and tumor necrosis factor alpha. This response is connected to RP-ILD in anti- MDA5-DM [1]. When cells detect viral double-stranded RNA, MDA5 activates, leading to interferon production through a complex pathway involving TANK-binding kinase 1, inhibitor of nuclear factor kappa-B kinase, and transcription factors. Over time, this can result in the production of anti-MDA5 antibodies [1].

MDA5-DM has 3 clinical phenotypes: pulmonary, skin–articular, and vascular. Previous findings and systemic reviews have revealed 3 clinical morphologies, each with varying degrees of pulmonary damage and inversely linked with survival and RP-ILD [1,4]. RP-ILD is the most important predictor of survival, making an individual 20 times more likely to develop RP-ILD in MDA5-DM than in MDA5-negative dermatomyositis [3]. RP-ILD in MDA5-DM poses a unique diagnostic challenge, often resembling acute respiratory distress syndrome. Key differentials include Pneumocystis jirovecii pneumonia and ILD exacerbation [9]. Distinguishing myositis-induced pulmonary illness is further complicated by muscle symptoms. A recent French study noted 36% of ICU-admitted patients with inflammatory myositis lacked extrapulmonary features, with MDA5-DM at 40% [9]. Timely identification is critical for lowering mortality [9]. Anti-MDA5 antibodies in juvenile dermatomyositis have distinct features: more constitutional symptoms and milder muscle involvement compared with other types [1]. They also often exhibit palmar papules, skin ulcers, and arthritis, setting them apart from other juvenile dermatomyositis forms [1].

Clinically amyopathic dermatomyositis (CADM) constitutes 5% to 20% of all dermatomyositis cases [11], and anti-MDA5 antibodies are present in 50% to 73% of patients with CADM, defining a distinct subtype with high risk of RP-ILD and vasculopathic skin lesions [12]. The clinical presentation of CADM often manifests with pathognomonic cutaneous features, including Gottron papules and sign, heliotrope rash, periungual telangiectasia, mechanic’s hands, and painful ulcerations or palmar papules, with an absence of objective muscle weakness for more than 6 months, although laboratory or imaging evidence of subclinical myositis can occur [12]. Diagnosis is supported by myositis-specific antibody testing (especially anti-MDA5) and imaging or biopsy exclusion of other causes [12]. Early combined immunosuppressive therapy is critical for survival in ILD-associated disease in CADM, while cutaneous-limited forms are managed with topical agents, antimalarial medications, or IVIG [4,13].

Anti-MDA5 antibody levels are linked to disease severity in MDA5-DM, especially in ILD and skin symptoms [4]. They help gauge treatment response and remission. Ro-52 antibodies, found in 60% of patients, may increase RP-ILD and skin vasculopathy risk [4]. Biomarkers, such as the FLAIR score, predict survival in CADM/ILD [4]. These antibodies, along with ferritin and interleukin 18 levels, normalize following effective treatment [4]. HRCT in MDA5-DM reveals specific patterns, such as ground-glass opacities and septal thickening [4]. Pneumomediastinum, a severe complication, is more common in MDA5-DM with ILD than in other myositis types [1,4,10]. Currently, there is no direct evidence linking COVID-19 to the development of anti-MDA5 antibodies or MDA5-DM [3]. Although COVID-19 can cause immune-related complications, such as cytokine storms, specific autoantibodies such as anti-MDA5 are uncommon in COVID-19 cases [3]. COVID-19 mRNA vaccines can activate MDA5 and innate immune sensors, triggering cellular activation and the production of immune mediators [3]. It has been reported that SARS-CoV-2 can activate RNA sensors like retinoic acid–inducible gene I and MDA5, despite the immune response, hinting at a potential role in disease development [3].

Severe RP-ILD associated with MDA5-DM often requires robust immunosuppression. A combination of steroids, tacrolimus, and cyclophosphamide has shown significantly better 6-month survival rates, compared with that of other treatments [6]. Plasmapheresis, alongside immunosuppressants, also improves survival rates [10]. A case series of 10 refractory RP-ILD cases, of which 6 received plasma exchange, were noted to achieve a 1-year survival rate of 100%, compared with 25% in the non-plasma exchange group. However, 20% to 30% mortality persisted overall, consistent with fatal outcomes despite maximal therapy [14]. JAK inhibitors, a newer class of drugs, may offer specific benefits by rapidly reducing interferon production and stopping cytokine storms. Case reports indicate the positive effects on survival, ferritin levels, and CT scores of tofacitinib in patients with MDA5-DM [3]. Tocilizumab, an interleukin-6 receptor inhibitor used for autoimmune and inflammatory conditions, has shown potential in treating anti-MDA5-associated ILD in some refractory patients [7,8,15], with improvements noted in clinical or radiological outcomes. However, results from studies are mixed, and larger trials are needed for definitive efficacy and safety evaluation [7,8,15]. Therefore, the use of tocilizumab in this context should be carefully considered on a case-by-case basis. Aggressive immunosuppression bi- or tri-therapy can cause infections and altered renal function, with cytomegalovirus reactivation being the most common [9]. Additionally, Pneumocystis jirovecii pneumonia is a recognized risk [9]. Nevertheless, in our series, despite vigorous treatment, we were unable to improve the survival of our patient with MDA5-DM who exhibited RP-ILD.

Conclusions

MDA5-DM is a rare and clinically diverse entity that can range from indolent skin-limited disease to life-threatening RP-ILD. This case series highlights the full clinical spectrum, from pediatric onset to fulminant adult disease. Despite common serological markers, patient outcomes varied dramatically, underscoring the importance of early diagnosis and prompt immunosuppressive intervention. Biomarkers such as ferritin, LDH, and anti-Ro52 antibodies can assist in prognostication [4]. Although newer treatments, such as JAK inhibitors and biologics, offer promise [3,7,15], traditional immunosuppression remains the mainstay therapy [6]. Multidisciplinary care, awareness of atypical presentations, and continued research into disease mechanisms and therapeutics are essential to improving survival in MDA5-DM.